20-F: Ehave, Inc. Reports Full Year 2024 Results: Losses Continue Amidst Going Concern Uncertainty

Ehave, Inc. reports a net loss of $2.75 million for 2024 and expresses substantial doubt about its ability to continue as a going concern.

Summary

• Ehave, Inc. reported a net loss of $2,748,874 for the year ended December 31, 2024, compared to a net loss of $2,409,397 in 2023.
• The company had no significant revenues from continuing operations in 2024 and 2023.
• As of December 31, 2024, Ehave had an accumulated deficit of $38,292,380 and a working capital deficit of $9,158,333.
• The company's independent auditors have expressed concern about its ability to continue as a going concern without additional capital.
• Ehave is focusing on developing its Ehave Dashboard, MegaTeam, and Ninja Reflex products, and exploring strategic alliances and partnerships.
• The company is subject to various healthcare laws and regulations, including HIPAA and the Anti-Kickback Statute.
• Ehave's common shares are quoted on the Pink Open Market, which is a limited and sporadic market.
• The company is considered a foreign private issuer and an emerging growth company, which provides certain exemptions from disclosure requirements.
• Management has identified material weaknesses in internal control over financial reporting.
• The company may be classified as a Passive Foreign Investment Company (PFIC), which could have negative tax consequences for U.S. investors.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to ongoing losses, concerns about going concern, and material weaknesses in internal control. While there are some positive aspects related to product development and strategic alliances, the overall financial situation is concerning.

Positives

• Ehave is developing the Ehave Dashboard, an extensible platform for condition-specific applications.
• The company is expanding MegaTeam and Ninja Reflex with additional game titles and participating in clinical studies.
• Ehave is forming strategic alliances with publishers of psychological assessments.
• The company is developing relationships with pharmaceutical and insurance companies.
• Ehave plans to utilize its mental health informatics platform and assets acquired from CureDash Inc., in January 2021, to optimize patient care and health outcomes in conjunction with Ketamine therapy for mental health.

Negatives

• Ehave, Inc. reported a net loss of $2,748,874 for the year ended December 31, 2024.
• The company had no significant revenues from continuing operations in 2024 and 2023.
• As of December 31, 2024, Ehave had an accumulated deficit of $38,292,380 and a working capital deficit of $9,158,333.
• The company's independent auditors have expressed concern about its ability to continue as a going concern without additional capital.
• The company is currently in default on its convertible notes.
• Management has identified material weaknesses in internal control over financial reporting.

Risks

• Ehave's limited operating history makes evaluating its business and future prospects difficult.
• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future.
• If Ehave is unable to obtain additional funding, its business operations will be harmed.
• The company's products may not be successful in gaining market acceptance.
• If Ehave is unable to keep up with rapid technological changes in its field, it will be unable to operate profitably.
• Many of Ehave's potential competitors are better established and have significantly greater resources.
• Developments or assertions relating to intellectual property rights could materially impact Ehave's business.
• The market for Ehave's products is immature and volatile.
• If Ehave fails to comply with applicable health information privacy and security laws, it may be subject to significant liabilities.
• A security breach or disruption or failure in a computer or communications systems could adversely affect us.
• The company may be classified as a Passive Foreign Investment Company (PFIC), which could have negative tax consequences for U.S. investors.

Future Outlook

Ehave anticipates continuing to incur losses and negative cash flows from operations and may not have sufficient resources to fund operations through the fourth quarter of 2025. The company plans to continue commercializing its products and raising capital through equity offerings, debt financings, and strategic partnerships.

Industry Context

Ehave operates in the mental healthcare and digital therapeutics market, which is a growing but competitive industry. The company faces competition from established players with greater resources and must navigate complex regulatory requirements.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific revenue figures or growth rates for comparable companies, it's difficult to assess Ehave's performance relative to its peers.
• Companies like Akili Interactive, Attentiv, Myndlift and C8Sciences are mentioned as competitors in the MegaTeam and Ninja Reflex game applications market.
• Epic, Allscripts and GE Healthcare are mentioned as leaders in the EHR market, but Ehave intends to focus specifically on Ketamine clinics.
• Novamind and Field Trip Health are mentioned as companies offering Ketamine infusion therapy, but KetaDash differentiates itself by providing treatments in a patient's home.

Related Party Transactions

• The company has entered into consulting contracts with each of its officers.
• On January 1, 2021, the company entered into an Executive Consulting Agreement with Benjamin Kaplan to serve as the company's CEO.
• On January 30, 2024, the company signed an agreement with a major shareholder for a $165,000 note payable.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment.
• Employees face uncertainty about the company's future and job security.
• Customers may be concerned about the long-term viability of the company and its products.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• Continued commercialization of products.
• Raising capital through equity offerings, debt financings, and strategic partnerships.
• Resolving material weaknesses in internal control over financial reporting.
• Monitoring and complying with healthcare laws and regulations.

Key Dates

Keywords

Ehave, mental health, digital therapeutics, KetaDash, MegaTeam, Ninja Reflex, financial results, going concern, losses, accumulated deficit, internal control, PFIC